Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx/Aventis Settle With FTC: Agency Says Cardizem CD Generic Not Delayed

Executive Summary

Aventis and Andrx' consent agreement with the Federal Trade Commission includes an acknowledgement by the agency that the patent litigation settlement between the two companies did not delay the advent of generic competition to Cardizem CD.

Related Content

Elan Naprelan FTC subpoena
Cardizem CD settlement
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm
Andrx naproxen ER approved
K-Dur Case: Reverse Payments Not “Established” Antitrust Violations – Judge
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs
Andrx/Aventis Cardizem CD Class Action Appeal Pending; State AGs Sue
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
FTC Hytrin Order Clears Path For Four Generics; Cardizem CD Case Filed



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts